Here, I report all of my funding and disclosures in accordance with ICMJE guidelines. I do not report small institutional funds such as the small Graduate Research Allocation Committee grants I have received in graduate school from UC Berkeley. This page is up to date as of November 8, 2021.

Funding

  • Graduate Research Fellowship, Greater Good Science Center, University of California, Berkeley; 2021-2022

  • NIH Biology and Biotechnology of Cell and Gene Therapy Training Program (T32GM139780), Stem Cell Center, University of California, Berkeley; 2021-2022

Disclosures

Consulting Fees

  • Epiodyne, Inc., 2018 - I served as a paid consultant to the company Epiodyne briefly in 2018. I do not have any existing relationships with this company or hold any stock in them.

Support for Attending Meetings and/or Travel

  • Alzheimer’s Association, 2016 - I received full support to attend the 2016 Alzheimer’s Association International Conference from the Alzheimer’s Association through their student volunteer program.

  • Deutches Zentrum für Neurodegenerative Erkrankungen (DZNE), 2019 - I received support to attend a meeting on locus coeruleus neuroimaging in Magdeburg, Germany from the Otto Von Guericke University Institut für Kognitive Neurologie Und Demenzforschung and DZNE.

  • Collaboratory on Research Definitions for Reserve and Resilience, 2021 - I received support to attend the 3rd Reserve & Resilience Workshop in Bethesda, Maryland.

Leadership or fiduciary role in other board, society, committee or advocacy group

  • Science Editor, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 2019-Present - I serve on the editorial board for the journal Alzheimer’s & Dementia. I am not compensated for this role.

  • Executive Committee Member, ISTAART, 2020-2022 - I serve on the executive committee for the neuromodulatory subcortical structures professional interest area of the International Society to Advance Alzheimer’s Research and Treatment (ISTAART). I am not compensated for this role.

Stock or Stock Options

  • Eiger Biopharmaceuticals, Inc - I purchased publicly traded stock in EIGR on July 20, 2021 and continue to hold these stocks. I had previously published results relevant to the potential performance of a drug, Lonafarnib, which the company owns. I have not at any point worked with EIGR or have access to any information that is not publicly available related to this drug or the company.